The tally of retractions in MEDLINE — one of the world’s largest databases of scientific abstracts — for the last fiscal year has just been released, and the number is: 664.
Earlier this year, we scratched our heads over the data from 2015, which showed retractions had risen dramatically, to 684. The figures for this fiscal year — which ended in September — have held relatively steadily at that higher number, only dropping by 3%. (For some sense of scale, there were just shy of 870,000 new abstracts indexed in MEDLINE in FY2016; 664 is a tiny fraction of this figure, and of course not all of the retractions were of papers published in FY2016.)
Of note: In FY2014, there were fewer than 500 retractions — creating an increase of nearly 40% between 2014 and 2015. (Meanwhile, the number of citations indexed by MEDLINE rose only few percentage points over the same time period.) Which means the retraction rate in the last two years is dramatically higher than in 2014.
We have often wondered whether the retraction rate would ever reach a plateau, as the community’s ability to find problems in the literature catches up with the amount of problems present in the literature. But based on two years of data, we can’t say anything definitive about that.
Here’s an illustration of retraction data from recent years:
(Followers of the field may recall that the number of retractions grew ten-fold from 2001 to 2010.)
Where we did see a significant change is in the number of errata, which are down by 27% from last year. As you can see below, FY2015 does appear to have been an outlier when it comes to corrections:
Of course, not all retractions will be indexed in MEDLINE, which focuses on the biomedical sciences. But as most readers know, the majority of retractions take place in biomedical sciences. (Click here to learn more about the difference between PubMed and MEDLINE.)
We’ll keep monitoring these patterns and update you if we spy anything else unusual.
Like Retraction Watch? Consider making a tax-deductible contribution to support our growth. You can also follow us on Twitter, like us on Facebook, add us to your RSS reader, sign up on our homepage for an email every time there’s a new post, or subscribe to our daily digest. Click here to review our Comments Policy. For a sneak peek at what we’re working on, click here.